Cargando…
Multi-Purpose Utility of Circulating Plasma DNA Testing in Patients with Advanced Cancers
Tumor genomic instability and selective treatment pressures result in clonal disease evolution; molecular stratification for molecularly targeted drug administration requires repeated access to tumor DNA. We hypothesized that circulating plasma DNA (cpDNA) in advanced cancer patients is largely deri...
Autores principales: | Perkins, Geraldine, Yap, Timothy A., Pope, Lorna, Cassidy, Amy M., Dukes, Juliet P., Riisnaes, Ruth, Massard, Christophe, Cassier, Philippe A., Miranda, Susana, Clark, Jeremy, Denholm, Katie A., Thway, Khin, Gonzalez De Castro, David, Attard, Gerhardt, Molife, L. Rhoda, Kaye, Stan B., Banerji, Udai, de Bono, Johann S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492590/ https://www.ncbi.nlm.nih.gov/pubmed/23144797 http://dx.doi.org/10.1371/journal.pone.0047020 |
Ejemplares similares
-
High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy
por: Perez-Lopez, Raquel, et al.
Publicado: (2017) -
Tissue-Based Approaches to Study Pharmacodynamic Endpoints in Early Phase Oncology Clinical Trials
por: Ang, Joo Ern, et al.
Publicado: (2012) -
Phase I trial outcomes in older patients with advanced solid tumours
por: Khan, K H, et al.
Publicado: (2016) -
Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials
por: Geuna, E, et al.
Publicado: (2015) -
Improving the outcome of patients with castration-resistant prostate cancer through rational drug development
por: Attard, G, et al.
Publicado: (2006)